Valuation : Damora Therapeutics, Inc.

Market Cap 1.66B 1.43B 1.35B 1.23B 2.3B 158B 2.31B 16.06B 6.17B 80.54B 6.22B 6.09B 254B P/E 2026 *
-13.4x
P/E 2027 * -13x
Enterprise Value 1.2B 1.03B 975M 884M 1.66B 114B 1.67B 11.58B 4.45B 58.1B 4.49B 4.39B 184B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
92.4%
Yield 2026 *
-
Yield 2027 * -
1 day+4.69%
1 week-6.52%
Current month-0.28%
1 month-7.44%
3 months+31.55%
6 months+6.56%
Current year+22.12%
1 week 25.63
Extreme 25.63
30.74
1 month 25.63
Extreme 25.63
33.56
Current year 16.5
Extreme 16.5001
34.89
1 year 2.53
Extreme 2.53
38.33
3 years 2.01
Extreme 2.01
38.33
5 years 2.01
Extreme 2.01
112.5
10 years 2.01
Extreme 2.01
449.75
Manager TitleAgeSince
Chief Executive Officer 55 2026-03-29
Director of Finance/CFO - 2026-04-30
Chief Tech/Sci/R&D Officer 60 2026-01-04
Director TitleAgeSince
Chairman 40 2026-03-22
Director/Board Member 42 2025-11-09
Director/Board Member 41 2025-11-09
Date Insider Type Main position Quantity % Market Cap. Importance
8/12/26 Free

Director

30,350 0.0493%
7/6/26 Sell

General Counsel

-245 0.0004%
5/1/26 Other

Chief Financial Officer

312,535 0.5077%
Change 5-day change 1-year change 3-year change Capi.($)
+4.69%-6.52%+903.57%+97.19% 1.66B
-0.71%-8.73%-4.56%+9.80% 46.05B
+0.21%-2.98%+340.68%+519.93% 43.59B
+1.74%-2.24%+37.28%+21.57% 42.35B
+1.38%-3.28%+3.23%+65.60% 38.86B
-1.44%-4.76%+10.26%+38.52% 32.24B
+0.87%-2.60% - - 17.16B
+0.75%-0.64%+18.07%+110.32% 16.28B
-0.31%-3.76%+12.33%+30.49% 14.32B
+1.93%-3.55%+74.20%+39.37% 13.03B
Average +0.74%-4.69%+155.01%+103.64% 26.55B
Weighted average by Cap. +0.14%-5.09%+78.95%+123.70%

Financials

2026 *2027 *
Net sales - -
Net income -125M -108M -102M -92.73M -174M -11.98B -175M -1.22B -467M -6.1B -471M -461M -19.26B -150M -129M -122M -111M -208M -14.34B -209M -1.45B -559M -7.3B -564M -552M -23.06B
Net Debt -462M -398M -377M -341M -640M -44.1B -644M -4.47B -1.72B -22.43B -1.73B -1.7B -70.89B -352M -303M -287M -260M -488M -33.61B -490M -3.41B -1.31B -17.1B -1.32B -1.29B -54.03B
Logo Damora Therapeutics, Inc.
Damora Therapeutics, Inc. is a biotechnology company that focuses on hematologic disorders. It is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms (MPN), including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. Its lead asset, DMR-001, is an investigational monoclonal antibody therapy targeting mutant calreticulin (mutCALR). It is developing candidates for treatment of essential thrombocythemia (ET), an MPN associated with the overproduction of platelets, and myelofibrosis, an MPN involving the overproliferation of blood cells and deposition of fibrous material in the bone marrow and spleen. DMR-002, an afucosylated antibody designed to enhance antibody-dependent cellular cytotoxicity and amplify natural immune killing of malignant cells. DMR-003, a bi-specific T-cell engager antibody designed to recruit and direct T-cell-mediated killing of malignant cells.
Employees
7
Date Price Change Volume
26-09-11 US$28.10 +4.69% 525,324
26-09-10 US$26.84 +2.17% 639,787
26-09-09 US$26.27 -9.94% 500,073
26-09-08 US$29.17 -2.96% 559,967
26-09-04 US$30.06 +7.36% 295,832
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
26.84USD
Average target price
44.67USD
Spread / Average Target
+66.42%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DMRA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!